Price
CHART BY
Frequently asked questions
What is Unicycive Therap's market capitalization?
What is the Earnings Per Share (EPS) for Unicycive Therap?
What are the analyst ratings and target price for Unicycive Therap's stock?
What is the EBITDA for Unicycive Therap?
What is the free cash flow of Unicycive Therap?
How many employees does Unicycive Therap have, and what sector and industry does it belong to?
What is the free float of Unicycive Therap's shares?
Financials
- Market Cap
- $177.17M
- EPS (TTM)
- -2.022
- Free Float
- 22.40M
- EBITDA (TTM)
- -$28.95M
- Free Cashflow (TTM)
- -$31.34M
Pricing
- 52W span
- 3.7211.00
Analyst Ratings
The price target is $43.75 and the stock is covered by 8 analysts.
Buy
8
Hold
0
Sell
0
Information
Unicycive Therapeutics, Inc. is a biotechnology company, which engages in developing novel treatments for kidney diseases. The firm investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent currently under review by the U.S. Food and Drug Administration (FDA) for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. The company was founded by Shalabh Gupta on August 18, 2016 and is headquartered in Los Altos, CA.
- Employees
- 21
- Industries
- Biotechnology
- Sector
- Health Care
Identifier
- Primary Ticker
- UNCY